Literature DB >> 22605898

Indacaterol (arcapta neohaler) for chronic obstructive pulmonary disease.

Rachel M Slaton, Danielle L Cruthirds.   

Abstract

Entities:  

Year:  2012        PMID： 22605898      PMCID： PMC3351870     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  27 in total

1.  Death in the United States, 2009.

Authors:  Arialdi M Miniño
Journal:  NCHS Data Brief       Date:  2011-07

2.  Effect of indacaterol on exercise endurance and lung hyperinflation in COPD.

Authors:  Denis E O'Donnell; Richard Casaburi; Walter Vincken; Luis Puente-Maestu; James Swales; David Lawrence; Benjamin Kramer
Journal:  Respir Med       Date:  2011-04-16       Impact factor: 3.415

3.  Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Authors:  Ronald Dahl; Kian Fan Chung; Roland Buhl; Helgo Magnussen; Vladimir Nonikov; Damon Jack; Patricia Bleasdale; Roger Owen; Mark Higgins; Benjamin Kramer
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

4.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Authors:  James F Donohue; Charles Fogarty; Jan Lötvall; Donald A Mahler; Heinrich Worth; Arzu Yorgancioglu; Amir Iqbal; James Swales; Roger Owen; Mark Higgins; Benjamin Kramer
Journal:  Am J Respir Crit Care Med       Date:  2010-05-12       Impact factor: 21.405

5.  Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

Authors:  Peter J Barnes; Stuart J Pocock; Helgo Magnussen; Amir Iqbal; Benjamin Kramer; Mark Higgins; David Lawrence
Journal:  Pulm Pharmacol Ther       Date:  2010-01-18       Impact factor: 3.410

6.  Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.

Authors:  Gregory Feldman; Thomas Siler; Niyati Prasad; Damon Jack; Simon Piggott; Roger Owen; Mark Higgins; Benjamin Kramer
Journal:  BMC Pulm Med       Date:  2010-03-08       Impact factor: 3.317

7.  A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

Authors:  Stephen Rennard; Theo Bantje; Stefano Centanni; Pascal Chanez; Alexander Chuchalin; Anthony D'Urzo; Oliver Kornmann; Sheryl Perry; Damon Jack; Roger Owen; Mark Higgins
Journal:  Respir Med       Date:  2008-05-13       Impact factor: 3.415

8.  Bronchodilator effects of indacaterol and formoterol in patients with COPD.

Authors:  J Beier; K-M Beeh; L Brookman; G Peachey; A Hmissi; S Pascoe
Journal:  Pulm Pharmacol Ther       Date:  2009-05-22       Impact factor: 3.410

9.  Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.

Authors:  Sanjeev Khindri; Ronald Sabo; Stuart Harris; Ralph Woessner; Simon Jennings; Anton F Drollmann
Journal:  BMC Pulm Med       Date:  2011-05-26       Impact factor: 3.317

10.  Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.

Authors:  Jorge Roig; Rosana Hernando; Ramon Mora
Journal:  Open Respir Med J       Date:  2009-03-12
View more
  2 in total

1.  Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction.

Authors:  Harm Maarsingh; Anouk Oldenburger; Bing Han; Annet B Zuidhof; Carolina R S Elzinga; Wim Timens; Herman Meurs; Ramadan B Sopi; Martina Schmidt
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

Review 2.  Indacaterol: a comprehensive review.

Authors:  Andrea Rossi; Guido Polese
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-07-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.